DNA Specimen Provenance Assay: Preventing Overdiagnosis of Prostate Cancer

Posted by | Nov 2018

Ted Schenberg, CEO of Strand Diagnostics, explains how the DNA Specimen Provenance Assay minimizes adverse effects in cancer patients due to specimen provenance complications (SPCs) in biopsy reporting. He also discusses the UroSeq™ hereditary prostate cancer panel test, which Strand Diagnostics introduced earlier this year.

Read More